Staff / Principal Software Engineer - Computational Chemistry / Molecu…
Genesis TherapeuticsSalary not specified
- Full Time
- Senior (5 to 8 years)
About Genesis Therapeutics
Genesis Therapeutics accelerates the development of new medicines by using artificial intelligence in drug discovery. The company combines 3D spatial graph modeling and molecular simulation to identify potential drug candidates and explore new chemical spaces. Unlike its competitors, Genesis Therapeutics focuses on strategic partnerships with other biotech and pharmaceutical companies, generating revenue through upfront payments and future earnings based on drug success. The goal is to transform the drug discovery process and bring new therapies to market.
Burlingame, CaliforniaHeadquarters
2019Year Founded
$272.5MTotal Funding
SERIES_BCompany Stage
AI & Machine Learning, BiotechnologyIndustries
51-200Employees
Benefits
Competitive salary
Equity
Medical, dental, & vision insurance
401(k) program
Risks
Competition from AI-driven companies like Insilico Medicine and Exscientia is increasing.
Over-reliance on partnerships could lead to financial instability if drugs aren't successful.
Rapid AI advancements may render current models like GEMS obsolete without updates.
Differentiation
Genesis Therapeutics uses AI to accelerate drug discovery with 3D spatial graph modeling.
The GEMS platform integrates deep learning, molecular simulations, and generative AI for drug design.
Strategic partnerships with Eli Lilly and Gilead highlight Genesis' industry collaboration strength.
Upsides
Partnership with NVIDIA enhances GEMS platform for targeting undruggable diseases.
$224 million equity investment boosts research and development capabilities.
Recognition as a 'Fierce 15' company underscores AI's role in breakthrough therapeutics.
Funding
Total raised$272.49 M
Latest valuation$1.12 B
StageSERIES_B
SEED
10/31/2019$4
$20.50 M